New insights into clinical trial for colostrinin™ in Alzheimer's disease

P. Szaniszlo, P. German, G. Hajas, D. N. Saenz, M. Kruzel, Istvan Boldogh

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The pathomechanism of Alzheimer's disease (AD) is multifactorial although the most popular hypotheses are centered on the effects of the misfolded, aggregated protein, amyloid beta (Aβ) and on Tau hyperphosphorylation. Objectives: Double blinded clinical trials were planned to demonstrate the effect of Colostrinin™ (CLN) on instrumental daily activities of AD patients. The potential molecular mechanisms by which CLN mediates its effects were investigated by gene expression profiling. Methods: RNAs isolated from CLN-treated cells were analyzed by high-density oligonucleotide arrays. Network and pathway analyses were performed using the Ingenuity Pathway Analysis software. Results: The Full Sample Analysis at week 15 showed a stabilizing effect of CLN on cognitive function in ADAS-cog (p = 0.02) and on daily function in IADL (p = 0.02). The overall patient response was also in favor of CLN (p = 0.03). Patients graded as mild on entry also showed a superior response of ADAS-cog compared to more advanced cases (p = 0.01). Data derived from microarray network analysis show that CLN elicits highly complex and multiphasic changes in the cells' transcriptome. Importantly, transcriptomal analysis showed that CLN alters gene expression of molecular networks implicated in Aβ precursor protein synthesis, Tau phosphorylation and increased levels of enzymes that proteolitically eliminate Aβ. In addition, CLN enhanced the defense against oxidative stress and decreased expression of inflammatory chemokines and cytokines, thereby attenuating inflammatory processes that precede Alzheimer's and other neurological diseases. Conclusion: Together these data suggest that CLN has promising potential for clinical use in prevention and therapy of Alzheimer's and other age-associated central nervous system diseases.

Original languageEnglish (US)
Pages (from-to)235-241
Number of pages7
JournalJournal of Nutrition, Health and Aging
Volume13
Issue number3
DOIs
StatePublished - Mar 2009

Fingerprint

Alzheimer Disease
Clinical Trials
colostrinine
Serum Amyloid A Protein
tau Proteins
Protein Precursors
Amyloid beta-Peptides
Central Nervous System Diseases
Gene Expression Profiling
Microarray Analysis
Oligonucleotide Array Sequence Analysis
Transcriptome
Chemokines
Cognition
Oxidative Stress
Software
Phosphorylation
RNA
Cytokines
Gene Expression

Keywords

  • AD
  • CLN
  • Network analysis

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Geriatrics and Gerontology

Cite this

New insights into clinical trial for colostrinin™ in Alzheimer's disease. / Szaniszlo, P.; German, P.; Hajas, G.; Saenz, D. N.; Kruzel, M.; Boldogh, Istvan.

In: Journal of Nutrition, Health and Aging, Vol. 13, No. 3, 03.2009, p. 235-241.

Research output: Contribution to journalArticle

Szaniszlo, P. ; German, P. ; Hajas, G. ; Saenz, D. N. ; Kruzel, M. ; Boldogh, Istvan. / New insights into clinical trial for colostrinin™ in Alzheimer's disease. In: Journal of Nutrition, Health and Aging. 2009 ; Vol. 13, No. 3. pp. 235-241.
@article{0311b4ab38094745a9d458876cf1f868,
title = "New insights into clinical trial for colostrinin™ in Alzheimer's disease",
abstract = "Background: The pathomechanism of Alzheimer's disease (AD) is multifactorial although the most popular hypotheses are centered on the effects of the misfolded, aggregated protein, amyloid beta (Aβ) and on Tau hyperphosphorylation. Objectives: Double blinded clinical trials were planned to demonstrate the effect of Colostrinin™ (CLN) on instrumental daily activities of AD patients. The potential molecular mechanisms by which CLN mediates its effects were investigated by gene expression profiling. Methods: RNAs isolated from CLN-treated cells were analyzed by high-density oligonucleotide arrays. Network and pathway analyses were performed using the Ingenuity Pathway Analysis software. Results: The Full Sample Analysis at week 15 showed a stabilizing effect of CLN on cognitive function in ADAS-cog (p = 0.02) and on daily function in IADL (p = 0.02). The overall patient response was also in favor of CLN (p = 0.03). Patients graded as mild on entry also showed a superior response of ADAS-cog compared to more advanced cases (p = 0.01). Data derived from microarray network analysis show that CLN elicits highly complex and multiphasic changes in the cells' transcriptome. Importantly, transcriptomal analysis showed that CLN alters gene expression of molecular networks implicated in Aβ precursor protein synthesis, Tau phosphorylation and increased levels of enzymes that proteolitically eliminate Aβ. In addition, CLN enhanced the defense against oxidative stress and decreased expression of inflammatory chemokines and cytokines, thereby attenuating inflammatory processes that precede Alzheimer's and other neurological diseases. Conclusion: Together these data suggest that CLN has promising potential for clinical use in prevention and therapy of Alzheimer's and other age-associated central nervous system diseases.",
keywords = "AD, CLN, Network analysis",
author = "P. Szaniszlo and P. German and G. Hajas and Saenz, {D. N.} and M. Kruzel and Istvan Boldogh",
year = "2009",
month = "3",
doi = "10.1007/s12603-009-0065-2",
language = "English (US)",
volume = "13",
pages = "235--241",
journal = "Journal of Nutrition, Health and Aging",
issn = "1279-7707",
publisher = "Springer Paris",
number = "3",

}

TY - JOUR

T1 - New insights into clinical trial for colostrinin™ in Alzheimer's disease

AU - Szaniszlo, P.

AU - German, P.

AU - Hajas, G.

AU - Saenz, D. N.

AU - Kruzel, M.

AU - Boldogh, Istvan

PY - 2009/3

Y1 - 2009/3

N2 - Background: The pathomechanism of Alzheimer's disease (AD) is multifactorial although the most popular hypotheses are centered on the effects of the misfolded, aggregated protein, amyloid beta (Aβ) and on Tau hyperphosphorylation. Objectives: Double blinded clinical trials were planned to demonstrate the effect of Colostrinin™ (CLN) on instrumental daily activities of AD patients. The potential molecular mechanisms by which CLN mediates its effects were investigated by gene expression profiling. Methods: RNAs isolated from CLN-treated cells were analyzed by high-density oligonucleotide arrays. Network and pathway analyses were performed using the Ingenuity Pathway Analysis software. Results: The Full Sample Analysis at week 15 showed a stabilizing effect of CLN on cognitive function in ADAS-cog (p = 0.02) and on daily function in IADL (p = 0.02). The overall patient response was also in favor of CLN (p = 0.03). Patients graded as mild on entry also showed a superior response of ADAS-cog compared to more advanced cases (p = 0.01). Data derived from microarray network analysis show that CLN elicits highly complex and multiphasic changes in the cells' transcriptome. Importantly, transcriptomal analysis showed that CLN alters gene expression of molecular networks implicated in Aβ precursor protein synthesis, Tau phosphorylation and increased levels of enzymes that proteolitically eliminate Aβ. In addition, CLN enhanced the defense against oxidative stress and decreased expression of inflammatory chemokines and cytokines, thereby attenuating inflammatory processes that precede Alzheimer's and other neurological diseases. Conclusion: Together these data suggest that CLN has promising potential for clinical use in prevention and therapy of Alzheimer's and other age-associated central nervous system diseases.

AB - Background: The pathomechanism of Alzheimer's disease (AD) is multifactorial although the most popular hypotheses are centered on the effects of the misfolded, aggregated protein, amyloid beta (Aβ) and on Tau hyperphosphorylation. Objectives: Double blinded clinical trials were planned to demonstrate the effect of Colostrinin™ (CLN) on instrumental daily activities of AD patients. The potential molecular mechanisms by which CLN mediates its effects were investigated by gene expression profiling. Methods: RNAs isolated from CLN-treated cells were analyzed by high-density oligonucleotide arrays. Network and pathway analyses were performed using the Ingenuity Pathway Analysis software. Results: The Full Sample Analysis at week 15 showed a stabilizing effect of CLN on cognitive function in ADAS-cog (p = 0.02) and on daily function in IADL (p = 0.02). The overall patient response was also in favor of CLN (p = 0.03). Patients graded as mild on entry also showed a superior response of ADAS-cog compared to more advanced cases (p = 0.01). Data derived from microarray network analysis show that CLN elicits highly complex and multiphasic changes in the cells' transcriptome. Importantly, transcriptomal analysis showed that CLN alters gene expression of molecular networks implicated in Aβ precursor protein synthesis, Tau phosphorylation and increased levels of enzymes that proteolitically eliminate Aβ. In addition, CLN enhanced the defense against oxidative stress and decreased expression of inflammatory chemokines and cytokines, thereby attenuating inflammatory processes that precede Alzheimer's and other neurological diseases. Conclusion: Together these data suggest that CLN has promising potential for clinical use in prevention and therapy of Alzheimer's and other age-associated central nervous system diseases.

KW - AD

KW - CLN

KW - Network analysis

UR - http://www.scopus.com/inward/record.url?scp=63249120050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63249120050&partnerID=8YFLogxK

U2 - 10.1007/s12603-009-0065-2

DO - 10.1007/s12603-009-0065-2

M3 - Article

C2 - 19262960

AN - SCOPUS:63249120050

VL - 13

SP - 235

EP - 241

JO - Journal of Nutrition, Health and Aging

JF - Journal of Nutrition, Health and Aging

SN - 1279-7707

IS - 3

ER -